Novartis ESMO Event Presentation

Baseline patient characteristics similar between the two arms and representative of intended population 177Lu-PSMA-617 (n = 234) ARPI change (n = 234) Age, years, median (range) 71 (43-94) 72 (53-91) White, n (%) 211 (90.2) 214 (91.5) ECOG performance status 0 146 (62.4) 115 (49.1) n (%) 1 86 (36.8) 114 (48.7) Gleason score 8-10, n (%) PSA, median (range), µg/L Haemoglobin, median (range), g/L Alkaline phosphatase, median (range), U/L Lactate dehydrogenase, median (range), U/L Site of disease n (%) Prior ARPI n (%) 129.0 (88-156) 103.5 (28-1319) 196.5 (124-999) 7 (3.0) Liver Lymph node 76 (32.5) 74 (31.6) Bone 205 (87.6) 203 (86.8) Abiraterone Enzalutamide 119 (50.9) 130 (55.6) 94 (40.2) Other 21 (9.0) 84 (35.9) 20 (8.5) 136 (58.1) 18.4 (0-1197) 128.0 (88-155) 100.0 (36-1727) 197.0 (66-1314) 13 (5.6) 107 (45.7) 14.9 (0-4224) 14 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation